SI2968302T1 - Combination of directly-acting antiviral agents and ribavarin for the treatment of patients with HCV - Google Patents
Combination of directly-acting antiviral agents and ribavarin for the treatment of patients with HCV Download PDFInfo
- Publication number
- SI2968302T1 SI2968302T1 SI201430517T SI201430517T SI2968302T1 SI 2968302 T1 SI2968302 T1 SI 2968302T1 SI 201430517 T SI201430517 T SI 201430517T SI 201430517 T SI201430517 T SI 201430517T SI 2968302 T1 SI2968302 T1 SI 2968302T1
- Authority
- SI
- Slovenia
- Prior art keywords
- combination
- ndps
- ribavirin
- use according
- patient
- Prior art date
Links
- IWUCXVSUMQZMFG-AFCXAGJDSA-N Ribavirin Chemical compound N1=C(C(=O)N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 IWUCXVSUMQZMFG-AFCXAGJDSA-N 0.000 title claims abstract 20
- 229960000329 ribavirin Drugs 0.000 title claims abstract 20
- HZCAHMRRMINHDJ-DBRKOABJSA-N ribavirin Natural products O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1N=CN=C1 HZCAHMRRMINHDJ-DBRKOABJSA-N 0.000 title claims abstract 18
- 239000003443 antiviral agent Substances 0.000 title claims abstract 5
- 150000003839 salts Chemical class 0.000 claims abstract 6
- 229940125904 compound 1 Drugs 0.000 claims abstract 5
- 102000014150 Interferons Human genes 0.000 claims abstract 4
- 229940125782 compound 2 Drugs 0.000 claims abstract 4
- 229940079322 interferon Drugs 0.000 claims abstract 4
- 108010050904 Interferons Proteins 0.000 claims abstract 3
- 241000711549 Hepacivirus C Species 0.000 claims 5
- 206010016654 Fibrosis Diseases 0.000 claims 2
- 230000007882 cirrhosis Effects 0.000 claims 2
- 208000019425 cirrhosis of liver Diseases 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- 241000134307 Hepatitis C virus genotype 1 Species 0.000 claims 1
- 241001466982 Hepatitis C virus genotype 5 Species 0.000 claims 1
- 241000143279 Hepatitis C virus genotype 6 Species 0.000 claims 1
- 208000010710 hepatitis C virus infection Diseases 0.000 claims 1
- 208000015181 infectious disease Diseases 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Virology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Gastroenterology & Hepatology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361783437P | 2013-03-14 | 2013-03-14 | |
| EP14725812.3A EP2968302B9 (en) | 2013-03-14 | 2014-03-14 | Combination of direct acting antiviral agents and ribavirin for treating hcv patients |
| PCT/US2014/027556 WO2014152635A1 (en) | 2013-03-14 | 2014-03-14 | Combination of direct acting antiviral agents and ribavirin for treating hcv patients |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SI2968302T1 true SI2968302T1 (en) | 2018-04-30 |
Family
ID=50771575
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SI201430517T SI2968302T1 (en) | 2013-03-14 | 2014-03-14 | Combination of directly-acting antiviral agents and ribavarin for the treatment of patients with HCV |
Country Status (28)
| Country | Link |
|---|---|
| US (1) | US20140274934A1 (https=) |
| EP (4) | EP3733180A1 (https=) |
| JP (3) | JP6563894B2 (https=) |
| KR (2) | KR101853605B1 (https=) |
| CN (3) | CN105007921B (https=) |
| AU (3) | AU2014239322B2 (https=) |
| BR (1) | BR112015020918A2 (https=) |
| CA (1) | CA2901818C (https=) |
| CY (1) | CY1121474T1 (https=) |
| DK (1) | DK2968302T3 (https=) |
| EA (2) | EA201890507A1 (https=) |
| ES (1) | ES2654109T3 (https=) |
| HK (1) | HK1255257A1 (https=) |
| HR (1) | HRP20171898T1 (https=) |
| HU (1) | HUE036069T2 (https=) |
| IL (2) | IL240445B (https=) |
| LT (1) | LT2968302T (https=) |
| MX (1) | MX2015012536A (https=) |
| NO (1) | NO3090119T3 (https=) |
| PL (1) | PL2968302T3 (https=) |
| PT (1) | PT2968302T (https=) |
| RS (1) | RS56735B1 (https=) |
| SG (2) | SG10201709840UA (https=) |
| SI (1) | SI2968302T1 (https=) |
| SM (1) | SMT201800017T1 (https=) |
| TW (2) | TW202002979A (https=) |
| WO (1) | WO2014152635A1 (https=) |
| ZA (1) | ZA201705080B (https=) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6563894B2 (ja) * | 2013-03-14 | 2019-08-21 | アッヴィ・インコーポレイテッド | Ｈｃｖ患者を治療するための直接的に作用する抗ウイルス剤とリバビリンとの併用 |
| WO2015153792A1 (en) * | 2014-04-02 | 2015-10-08 | Abbvie Inc. | Methods for treating hcv |
| US11484534B2 (en) | 2013-03-14 | 2022-11-01 | Abbvie Inc. | Methods for treating HCV |
| US20150119400A1 (en) * | 2013-10-25 | 2015-04-30 | Abbvie, Inc. | Methods for treating hcv |
| EP3082808A1 (en) * | 2013-12-19 | 2016-10-26 | AbbVie Inc. | Methods for treating liver transplant recipients |
| US20160375017A1 (en) | 2015-06-26 | 2016-12-29 | Abbvie Inc. | Solid Pharmaceutical Compositions for Treating HCV |
| CN111907220B (zh) | 2016-01-08 | 2022-09-20 | 恩图鲁斯特咨询卡有限公司 | 具有卡片返回路径的卡片印刷机构 |
| EA201892448A1 (ru) | 2016-04-28 | 2019-06-28 | Эмори Юниверсити | Алкинсодержащие нуклеотидные и нуклеозидные терапевтические композиции и связанные с ними способы применения |
| US20180085330A1 (en) * | 2016-09-23 | 2018-03-29 | Abbvie Inc. | Dose Adjustment |
| JP2018131439A (ja) * | 2017-02-14 | 2018-08-23 | アッヴィ・インコーポレイテッド | Ｈｃｖを処置する方法 |
| CA2981993A1 (en) * | 2017-08-02 | 2019-02-02 | Abbvie Inc. | Methods for treating hcv |
| CN108329332A (zh) * | 2018-03-16 | 2018-07-27 | 安徽华昌高科药业有限公司 | 一种制备Glecaprevir的方法 |
| EP3773753A4 (en) * | 2018-04-10 | 2021-12-22 | ATEA Pharmaceuticals, Inc. | TREATMENT OF PATIENTS INFECTED WITH THE HEPATITIS C VIRUS WITH CIRRHOSIS |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2011522862A (ja) * | 2008-06-10 | 2011-08-04 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | テラプレビル（Ｔｅｌａｐｒｅｖｉｒ）投薬養生法 |
| EA020031B1 (ru) * | 2009-06-11 | 2014-08-29 | Эббви Бахамаз Лтд. | Противовирусные соединения |
| US9394279B2 (en) | 2009-06-11 | 2016-07-19 | Abbvie Inc. | Anti-viral compounds |
| US8937150B2 (en) * | 2009-06-11 | 2015-01-20 | Abbvie Inc. | Anti-viral compounds |
| JP5857053B2 (ja) * | 2010-09-21 | 2016-02-10 | エナンタ ファーマシューティカルズ インコーポレイテッド | 大環式プロリン由来ｈｃｖセリンプロテアーゼ阻害剤 |
| DE202012012955U1 (de) | 2011-10-21 | 2014-07-14 | Abbvie Inc. | Eine Kombination aus mindestens zwei direkt wirkenden antiviralen Wirkstoffen (DAAs) für die Verwendung zur Behandlung von HCV |
| EP2583677A3 (en) | 2011-10-21 | 2013-07-03 | Abbvie Inc. | Methods for treating HCV comprising at least two direct acting antiviral agent, ribavirin but not interferon. |
| JP6563894B2 (ja) * | 2013-03-14 | 2019-08-21 | アッヴィ・インコーポレイテッド | Ｈｃｖ患者を治療するための直接的に作用する抗ウイルス剤とリバビリンとの併用 |
-
2014
- 2014-03-14 JP JP2016502479A patent/JP6563894B2/ja not_active Expired - Fee Related
- 2014-03-14 EP EP20167304.3A patent/EP3733180A1/en not_active Withdrawn
- 2014-03-14 DK DK14725812.3T patent/DK2968302T3/en active
- 2014-03-14 SG SG10201709840UA patent/SG10201709840UA/en unknown
- 2014-03-14 TW TW108114285A patent/TW202002979A/zh unknown
- 2014-03-14 ES ES14725812.3T patent/ES2654109T3/es active Active
- 2014-03-14 CN CN201480014994.0A patent/CN105007921B/zh not_active Expired - Fee Related
- 2014-03-14 SG SG11201507361YA patent/SG11201507361YA/en unknown
- 2014-03-14 WO PCT/US2014/027556 patent/WO2014152635A1/en not_active Ceased
- 2014-03-14 TW TW103109528A patent/TWI678205B/zh not_active IP Right Cessation
- 2014-03-14 CA CA2901818A patent/CA2901818C/en active Active
- 2014-03-14 EP EP21172004.0A patent/EP3915559A1/en not_active Withdrawn
- 2014-03-14 PT PT147258123T patent/PT2968302T/pt unknown
- 2014-03-14 AU AU2014239322A patent/AU2014239322B2/en not_active Ceased
- 2014-03-14 HR HRP20171898TT patent/HRP20171898T1/hr unknown
- 2014-03-14 SM SM20180017T patent/SMT201800017T1/it unknown
- 2014-03-14 EP EP14725812.3A patent/EP2968302B9/en not_active Revoked
- 2014-03-14 PL PL14725812T patent/PL2968302T3/pl unknown
- 2014-03-14 US US14/210,858 patent/US20140274934A1/en not_active Abandoned
- 2014-03-14 EA EA201890507A patent/EA201890507A1/ru unknown
- 2014-03-14 MX MX2015012536A patent/MX2015012536A/es unknown
- 2014-03-14 EA EA201591701A patent/EA030482B1/ru not_active IP Right Cessation
- 2014-03-14 SI SI201430517T patent/SI2968302T1/en unknown
- 2014-03-14 KR KR1020157029564A patent/KR101853605B1/ko not_active Expired - Fee Related
- 2014-03-14 CN CN201810204041.0A patent/CN108187056A/zh active Pending
- 2014-03-14 BR BR112015020918A patent/BR112015020918A2/pt not_active Application Discontinuation
- 2014-03-14 KR KR1020187011379A patent/KR20180045055A/ko not_active Abandoned
- 2014-03-14 LT LTEP14725812.3T patent/LT2968302T/lt unknown
- 2014-03-14 CN CN201811345144.5A patent/CN109908353A/zh active Pending
- 2014-03-14 RS RS20171264A patent/RS56735B1/sr unknown
- 2014-03-14 EP EP17189252.4A patent/EP3318258B1/en not_active Revoked
- 2014-03-14 HU HUE14725812A patent/HUE036069T2/hu unknown
- 2014-12-19 NO NO14823980A patent/NO3090119T3/no unknown
-
2015
- 2015-08-09 IL IL240445A patent/IL240445B/en active IP Right Grant
-
2017
- 2017-07-26 ZA ZA2017/05080A patent/ZA201705080B/en unknown
- 2017-12-06 CY CY20171101278T patent/CY1121474T1/el unknown
-
2018
- 2018-04-12 AU AU2018202581A patent/AU2018202581B2/en not_active Ceased
- 2018-11-09 HK HK18114396.1A patent/HK1255257A1/en unknown
-
2019
- 2019-05-07 JP JP2019087535A patent/JP2019167347A/ja active Pending
- 2019-07-08 IL IL267927A patent/IL267927A/en unknown
- 2019-07-24 JP JP2019135865A patent/JP2019214585A/ja active Pending
-
2020
- 2020-03-05 AU AU2020201656A patent/AU2020201656A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SI2968302T1 (en) | Combination of directly-acting antiviral agents and ribavarin for the treatment of patients with HCV | |
| HRP20201575T1 (hr) | Kombinacija dva protuvirusna sredstva namijenjena liječenju hepatitisa c | |
| JP2014530874A5 (https=) | ||
| MX388482B (es) | Métodos para tratar el virus de la hepatitis c. | |
| WO2015061294A8 (en) | Use of sting agonists to treat chronic hepatitis b virus infection | |
| EP2583677A3 (en) | Methods for treating HCV comprising at least two direct acting antiviral agent, ribavirin but not interferon. | |
| HRP20201953T1 (hr) | Postupci i farmaceutski pripravci za liječenje virusne infekcije hepatitisom b | |
| RU2013148779A (ru) | Лечение инфекции вируса гепатита в по отдельности или в комбинации с вирусом гепатита дельта и родственных заболеваний печени | |
| JP2016513703A5 (https=) | ||
| MD20140058A2 (en) | Compositions and methods for treating hepatitis C virus | |
| MX2010008148A (es) | Métodos de tratamiento de infecciones virales. | |
| RU2015114543A (ru) | Способы лечения гепатита с | |
| WO2015084741A3 (en) | Methods of treating hepatitis c virus infection in subjects with cirrhosis | |
| HK1255481A1 (zh) | 用於治疗hcv的方法 | |
| RU2015114566A (ru) | Способы лечения гепатита с | |
| NZ588655A (en) | Treatment of hepatitis c virus infections with telaprevir (vx-950) in patients non-responsive to treatment with pegylated interfer0n-alpha-2a/2b and ribavirin | |
| MX2016012722A (es) | Metodos para tratar el virus de la hepatitis c. | |
| EA201491652A1 (ru) | Средство для лечения вирусного гепатита с | |
| WO2014122537A3 (en) | Pharmaceutical compositions and methods of treating hepatitis c virus infection using a combination of hydroxychloroquine and ribavirin | |
| MX2016002856A (es) | Metodo para la prevencion o tratamiento de enfermedades asociadas con una reduccion en la densidad de receptores de interferon. | |
| NZ631789A (en) | Combination of direct acting antiviral agents and ribavirin for treating hcv patients | |
| MX2020001422A (es) | Metodos para el tratamiento de hcv. | |
| MX2018001905A (es) | Metodos para el tratamiento del virus de hepatitis c (vhc). | |
| Kawaoka | Peginterferon-alfa-2b/ribavirin | |
| EA201892732A1 (ru) | Противовирусные средства для лечения гепатита в |